Landos Biopharma Reports Fourth Quarter and Full Year 2021
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...
Roger Adsett Landos Biopharma Chris Garabedian Tim Mayleben Development Expenses Clinical Development Updates
Source: globenewswire.com